Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients

Hyperuricemia Clinical Trial

Official title:

Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03149939
• Other study ID #: BN-0316
• Status: Completed
• Phase: N/A
• First received: May 10, 2017
• Last updated: May 10, 2017
• Start date: January 1, 2017
• Est. completion date: May 1, 2017

Study information

• Verified date: May 2017
• Source: Benha University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Hyperuricemia is not infrequently encountered among hemodialysis patients. However, there is no clear data about use of febuxostat among hemodialysis patients, apart from very small case series. The aim of this study is to investigate the efficacy of using febuxostat for the treatment of Hyperuricemia among hemodialysis patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: May 1, 2017
• Est. primary completion date: April 1, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Age above 18 years

• Hemodialysis patient

• Hyperuricemia (Uric acid level above 6.0 mg/dL in females and 7.0 mg/dL in males)

Exclusion Criteria:

• Patient currently and/or recently received drugs for hyperuricemia within the last three months

• Patient had recent (within 3 months) change of erythropoiesis stimulating drugs or other drug known to increase uric acid e.g furosemide

Related Conditions & MeSH terms

• Hemodialysis Complication
• Hyperuricemia

Intervention

Drug:
• Febuxostat 40 milligramsTablet
Febuxostat 40 milligramsTablet every other day for 3 months

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Benha University	New Jeddah Clinic Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in serum uric acid	Change in serum uric acid after 3 months of Febuxostat 40 milligrams Tablet therapy	at three months of Febuxostat 40 milligrams Tablet therapy